In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus
(HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently …

The host immune system plays an important role in chronic hepatitis B (CHB), both in viral
clearance and hepatocellular damage. Advances in our understanding of the natural history …

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B
(CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis …

These are the first World Health Organization (WHO) guidelines for the prevention care and
treatment of persons living with CHB infection and complement similar recent published …

Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment
of chronic hepatitis B virus (HBV) infections. We have studied whether levels of serum HBV …

BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of
patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding …

Background & Aims Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater
plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug …

This report presents the recommendations of the WHO Expert Committee responsible for
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …

Tenofovir alafenamide (TAF) is a prodrug of tenofovir (TFV) currently in clinical evaluation for
treatment for HIV and hepatitis B virus (HBV) infections. Since the target tissue for HBV is the …

Current therapies of chronic hepatitis B (CHB) remain limited to either pegylated interferon-α
(Peg-IFN-α), or one of the five approved nucleoside analog (NA) treatments. Although viral …